An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2

作者：

Dimopoulos, Meletios ^{[1
]}

Grosicki, Sebastian ^{[2
]}

Jedrzejczak, Wieslaw ^{[3
]}

Nahi, Hareth ^{[4
]}

Gruber, Astrid ^{[4
]}

Hansson, Markus ^{[5
]}

Byrne, Catriona ^{[6
]}

Labotka, Richard ^{[6
]}

Teng, Zhaoyang ^{[6
]}

Yang, Huyuan ^{[6
]}

Grzasko, Norbert ^{[7
,8
]}

Kumar, Shaji ^{[9
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Athens, Greece

[2] Silesian Med Univ Katowice, Katowice, Poland

[3] Med Univ Warsaw, Warsaw, Poland

[4] Karolinska Univ Hosp, Stockholm, Sweden

[5] Skane Univ Hosp, Lund, Sweden

[6] Millennium Pharmaceut Inc, Cambridge, MA USA

[7] Med Univ Lublin, Lublin, Poland

[8] St Johns Canc Ctr, Lublin, Poland

[9] Mayo Clin, Rochester, MN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷

关键词：

D O I：

10.1016/j.clml.2017.07.148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-135

引用

页码：S333 / S334

页数：2

共 50 条

[41] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[42] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Kohmei Kubo
Mitsuo Hori
Kensuke Ohta
Hiroshi Handa
Kiyohiko Hatake
Morio Matsumoto
Shotaro Hagiwara
Kazuteru Ohashi
Chiaki Nakaseko
Kenshi Suzuki
Shigeki Ito
Gen Kinoshita
Suresh G. Shelat
Masafumi Miyoshi
Naoki Takezako
International Journal of Hematology, 2020, 111 : 65 - 74
[43] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Kubo, Kohmei
Hori, Mitsuo
Ohta, Kensuke
Handa, Hiroshi
Hatake, Kiyohiko
Matsumoto, Morio
Hagiwara, Shotaro
Ohashi, Kazuteru
Nakaseko, Chiaki
Suzuki, Kenshi
Ito, Shigeki
Kinoshita, Gen
Shelat, Suresh G.
Miyoshi, Masafumi
Takezako, Naoki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 65 - 74
[44] An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma
Nishihori, Taiga
Baz, Rachid
Shain, Kenneth
Kim, Jongphil
Ochoa-Bayona, Jose L.
Yue, Binglin
Sullivan, Daniel
Dalton, William
Alsina, Melissa
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) : 426 - 435
[45] A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)
Facon, Thierry
San-Miguel, Jesus
Usmani, Saad Z.
Dimopoulos, Meletios A.
Kumar, Shaji K.
Mateos, Maria-Victoria
Cavo, Michele
Heeg, Bart
Van Beekhuizen, Sophie
Pisini, Marta
Nair, Sandhya
Lam, Annette
Slavcev, Mary
He, Jianming
BLOOD, 2019, 134
[46] Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Dimopoulos, Meletios A.
Cheung, Matthew C.
Roussel, Murielle
Liu, Ting
Gamberi, Barbara
Kolb, Brigitte
Derigs, H. Guenter
Eom, HyeonSeok
Belhadj, Karim
Lenain, Pascal
Van der Jagt, Richard
Rigaudeau, Sophie
Dib, Mamoun
Hall, Rachel
Jardel, Henry
Jaccard, Arnaud
Tosikyan, Axel
Karlin, Lionel
Bensinger, William
Schots, Rik
Leupin, Nicolas
Chen, Guang
Marek, Jennifer
Ervin-Haynes, Annette
Facon, Thierry
HAEMATOLOGICA, 2016, 101 (03) : 363 - 370
[47] CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY
Bringhen, S.
Musto, P.
Gay, F.
Giuliani, N.
Liberati, A. M.
Pautasso, C.
Ponticelli, E.
De Paoli, L.
Zambello, R.
Ciccone, G.
Carella, A. M.
Boccadoro, M.
Sonneveld, P.
Palumbo, A.
HAEMATOLOGICA, 2016, 101 : 520 - 520
[48] Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study
Dimopoulos, Meletios
Chng, Wee Joo
Iida, Shinsuke
Mateos, Maria-Victoria
Morgan, Gareth
Lonial, Sagar
Spicka, Ivan
Quach, Hang
Oriol, Albert
Hajek, Roman
Garg, Mamta
Giuliani, Nicola
Beksac, Meral
Katodritou, Eirini
Bringhen, Sara
Li, Cong
Zhang, Xiaoquan
Labotka, Richard
Rajkumar, Vincent
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S95 - S95
[49] A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Kanellias, Nikolaos
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2022, 140 : 4405 - 4406
[50] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
LEUKEMIA, 2022, 36 (04) : 1066 - 1077

← 1 2 3 4 5 →